Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Childhood Brain Stem Neoplasm, Childhood Lymphoma, Childhood Solid Neoplasm, Pineal Region Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Visual Pathway Glioma or Refractory Central Nervous System Neoplasm
and you are
between 12 and 21
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

Provided treatments

  • Drug: Entinostat
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02780804. The sponsor of the trial is National Cancer Institute (NCI) and it is looking for 36 volunteers for the current phase.
Official trial title:
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma